header logo image


Page 700«..1020..699700701702..710720..»

[2020 GUIDE] Global 3D Cell Culture Market : Emerging Innovations Radically Changing The World Industry – Sound On Sound Fest

February 18th, 2020 5:49 pm

Global 3D Cell Culture Market 2020 information: by type (Scaffold-based, Scaffold-free), by end-use/application (Cancer Research, Stem Cell Research, Drug Discovery, Regererative Medicine) by Region (Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa); Forecast till 2028, Market.biz also offering latest industry research value according to the requirement.This report provides you themost up-to-date 3D Cell Culture data in the industry reports, we help you gain a much clearer perspective on the actual 3D Cell Culture market situation, trends, andfuture outlook for different segments.

Tailor-MadeGlobal 3D Cell Culture Market Research Report.

Well-Structured, Analyzed and Explained By Market.biz.

Our report will help you find what you looking for. Get FREE sample PDF:https://market.biz/report/global-3d-cell-culture-market-icrw/134185/#requestforsample

Below is a full list of the ELEMENTs in the Global 3D Cell Culture Industry, which can help organizations to survive and develop their self.

A Regional market Analysis is a quantitative and qualitative assessment of a 3D Cell Culture market. It looks into the size of the 3D Cell Culture business by 2020 both in volume and in value, the various customer segments and 3D Cell Culture buying patterns, the competition, and the economic environment in terms of barriers to entry and regulation.Knowledge is power. It helps businesses strengthen their position. Use market research to gain a better perspective and understanding of 3D Cell Culture market and target audience and ensure you stay ahead of the competition. These regions include-North America, Asia-Pacific, Europe, Africa, South America and the Rest of the world.Also, countries included areU.S., Canada, Mexico, U.K., France, Germany, Italy, China, India, Russia, The Middle East, South-East Asiaand so on.

The 3D Cell Culture Market size is a key component of strategic marketing planning. Knowledge of the size of the target 3D Cell Culture industryallows you to fully assess opportunities and accurately plan your approach and your investments wisely. It provides insights that can drive the future success of the 3D Cell Culture business, including 3D Cell Culture market size, or a total number of buyers for the product or service from different regions. An accurate understanding of market size will provide you with a number of significant advantages that will help you keep your business grow over time. The estimated 3D Cell Culture business value is USDXXbillion in 2028.

Any investment that offers you the benefit of compounding can help you double your investment and build wealth. So, we have calculated 3D Cell Culture Market Compound annual growth rate (CAGR) that shows how much a ones investment grew over a specific period. This report discusses how different 3D Cell Culture industry investments have performed over time. The 3D Cell Culture Industry is growing at a good CAGR of XX%. 3D Cell Culture Market is expected to grow to nearly $XX billion in the coming years.

Herein, we identified direct or indirect market competitors and at the same time,we comprehendedtheir mission, vision, core values, 3D Cell Culture niche market, strengths, and weaknesses. We have provided Porters five forces. It includes three forces from horizontal competition- 1. the threat of substitute products or services, 2. the threat of established3D Cell Culturerivals, 3. the threat of new entrants- and two others from vertical competition1. the bargaining power of3D Cell Culturesuppliers.2. the bargaining power of3D Cell Culturecustomers.Market.bizrecognizes the following companies as the key players in the global 3D Cell Culturemarket that includes-

Insphero, N3d Bioscience, Merck Kgaa, Thermo Fisher Scientific, 3D Biotek, Lonza Group, Kuraray Co, Reprocell orporated and Corning.

It refers to the behavior of the3D Cell Culture consumers in the marketplace and the underlying motives for thosebehavioral trends. Also, here, psychological, personal, and social consumer behavior is studied through focus groups, surveys, and tracking sales history. Our consumer behavior study helps businesses to understand what their consumers value. As a result, 3D Cell Culture businesses can craft their messaging based on what is most important to the subset of the market they are targeting. Not all consumers value the same benefits, so its important for businesses to segment their consumer base.

Finally,with the help of complete research of 3D Cell Culture Market 2020 provides knowledgeable data to the clients using figures, graphs, and flowcharts in the report, the experts represented the analyzed data in a better understandable way. It can assist an individual in making business decisions that can cause achieving swift business growth in 3D Cell Culture business across the world. Also, it discusses business challenges like- Which factors are contributing to the negative or positive growth of the market?

Want to customize this report? Enquire Herehttps://market.biz/report/global-3d-cell-culture-market-icrw/134185/#inquiry

Feel free to share your specific requirements if any, so that we can offer a tailor-made3D Cell Culturereport to suits your requirements.

Contact Us:

Market.Biz (Powered by Prudour Pvt. Ltd.)

Email ID:inquiry@market.biz

Telephone: +1(857)5982522

Link:
[2020 GUIDE] Global 3D Cell Culture Market : Emerging Innovations Radically Changing The World Industry - Sound On Sound Fest

Read More...

Autologous Stem Cell And Non-Stem Cell Based Therapies Market 2020-2025 Booming || Leadinf Players Fibrocell, Genesis Biopharma, Georgia Health…

February 17th, 2020 9:55 pm

TheGlobalAutologous Stem Cell and Non-Stem Cell Based Therapies Marketis expected to reach USD113.04 billion by 2025, from USD 87.59 billion in 2017 growing at a CAGR of 3.7% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2015 & 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

For In depth Information Get Sample Copy of this Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

Some of the major players operating in the global autologous stem cell and non-stem cell based therapies market areAntria (Cro), Bioheart, Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Genesis Biopharma, Georgia Health Sciences University, Neostem, Opexa Therapeutics, Orgenesis, Regenexx, Regeneus, Tengion, Tigenix, Virxsys and many more.

The data and information included in this Global Autologous Stem Cell And Non-Stem Cell Based Therapies business report helps businesses take sound decisions and plan about the advertising and sales promotion strategy more successfully. This Autologous Stem Cell And Non-Stem Cell Based Therapies market research report is generated by taking into account a range of objectives of market research that are vital for the clients success. This report also includes strategic profiling of key players in the market, systematic analysis of their core competencies, and draws a competitive landscape for the Healthcare industry. The Global Autologous Stem Cell And Non-Stem Cell Based Therapies business report includes market shares for global, Europe, North America, Asia Pacific and South America.

Market Definition:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

In autologous stem-cell transplantation persons own undifferentiated cells or stem cells are collected and transplanted back to the person after intensive therapy. These therapies are performed by means of hematopoietic stem cells, in some of the cases cardiac cells are used to fix the damages caused due to heart attacks. The autologous stem cell and non-stem cell based therapies are used in the treatment of various diseases such as neurodegenerative diseases, cardiovascular diseases, cancer and autoimmune diseases, infectious disease.

According to World Health Organization (WHO), cardiovascular disease (CVD) causes more than half of all deaths across the European Region. The disease leads to death or frequently it is caused by AIDS, tuberculosis and malaria combined in Europe. With the prevalence of cancer and diabetes in all age groups globally the need of steam cell based therapies is increasing, according to article published by the US National Library of Medicine National Institutes of Health, it was reported that around 382 million people had diabetes in 2013 and the number is growing at alarming rate which has increased the need to improve treatment and therapies regarding the diseases.

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

Market Segmentation:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Competitive Analysis:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

The global autologous stem cell and non-stem cell based therapies market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of autologous stem cell and non-stem cell based therapies market for global, Europe, North America, Asia Pacific and South America.

Major Autologous Stem Cell and Non-Stem Cell Based Therapies Market Drivers and Restraints:

Introduction of novel autologous stem cell based therapies in regenerative medicine

Reduction in transplant associated risks

Prevalence of cancer and diabetes in all age groups

High cost of autologous cellular therapies

Lack of skilled professionals

Customization of the Report:

Key benefits of buying the Autologous Stem Cell And Non-Stem Cell Based Therapies Market Report:

This Autologous Stem Cell And Non-Stem Cell Based Therapies Market report will enable both of the sides in market be an established firm or a relative new entrant. It helps the established firms to know about the moves which are being performed by their competitors and also helps the new entrants by educating them about the market situations and the industry trends. This Autologous Stem Cell And Non-Stem Cell Based Therapies Market report is quite fruitful in helping to understand the market definition and all the aspects of the market including the CAGR value and key profiles.

Speak to Author of the report @https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:[emailprotected]

Go here to see the original:
Autologous Stem Cell And Non-Stem Cell Based Therapies Market 2020-2025 Booming || Leadinf Players Fibrocell, Genesis Biopharma, Georgia Health...

Read More...

Stem Cell Assay Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis and Forecast by 2026 – Instant Tech News

February 17th, 2020 9:55 pm

Stem Cell Assay Market Overview:

Global Stem Cell Assay market was valued at USD 536.53million in 2016 and is projected to reach USD 2858.95millionby 2025, growing at a CAGR of 20.43% from 2017 to 2025.

In the report, we thoroughly examine and analyze the Global market for Stem Cell Assay so that market participants can improve their business strategy and ensure long-term success. The reports authors used easy-to-understand language and complex statistical images, but provided detailed information and data on the global Stem Cell Assay market. This report provides players with useful information and suggests result-based ideas to give them a competitive advantage in the global Stem Cell Assay market. Show how other players compete in the global Stem Cell Assay market and explain the strategies you use to differentiate yourself from other participants.

The researchers provided quantitative and qualitative analyzes with evaluations of the absolute dollar opportunity in the report. The report also includes an analysis of Porters Five Forces and PESTLE for more detailed comparisons and other important studies. Each section of the report offers players something to improve their gross margins, sales and marketing strategies, and profit margins. As a tool for insightful market analysis, this report enables players to identify the changes they need to do business and improve their operations. You can also identify key electrical bags and compete with other players in the global Stem Cell Assay market.

Request a Report Brochure @ https://www.verifiedmarketresearch.com/download-sample/?rid=24266&utm_source=ITN&utm_medium=003

Top 10 Companies in the Stem Cell Assay Market Research Report:

GE Healthcare, Promega Corporation, Thermo Fisher Scientific Pvt. Merck Millipore, Cell Bio Labs, Hemogenix, Stem Cell Technologies, Bio Rad, R&D Systems, Cellular Dynamics International.

Stem Cell Assay Market Competition:

Each company evaluated in the report is examined for various factors such as the product and application portfolio, market share, growth potential, future plans and recent developments. Readers gain a comprehensive understanding and knowledge of the competitive environment. Most importantly, this report describes the strategies that key players in the global Stem Cell Assay market use to maintain their advantage. It shows how market competition will change in the coming years and how players are preparing to anticipate the competition.

Stem Cell Assay Market Segmentation:

The analysts who wrote the report ranked the global Stem Cell Assay market by product, application, and region. All sectors were examined in detail, focusing on CAGR, market size, growth potential, market share and other important factors. The segment studies included in the report will help players focus on the lucrative areas of the global Stem Cell Assay market. Regional analysis will help players strengthen their base in the major regional markets. This shows the opportunities for unexplored growth in local markets and how capital can be used in the forecast period.

Regions Covered by the global market for Smart Camera:

Middle East and Africa (GCC countries and Egypt)North America (USA, Mexico and Canada)South America (Brazil, etc.)Europe (Turkey, Germany, Russia, Great Britain, Italy, France etc.)Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266&utm_source=ITN&utm_medium=003

Table of Content

1 Introduction of Stem Cell Assay Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Assay Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Assay Market, By Deployment Model

5.1 Overview

6 Stem Cell Assay Market, By Solution

6.1 Overview

7 Stem Cell Assay Market, By Vertical

7.1 Overview

8 Stem Cell Assay Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Assay Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Assay-Market/?utm_source=ITN&utm_medium=003

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Assay Market Size, Stem Cell Assay Market Growth, Stem Cell Assay Market Forecast, Stem Cell Assay Market Analysis, Stem Cell Assay Market Trends, Stem Cell Assay Market

Read more from the original source:
Stem Cell Assay Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis and Forecast by 2026 - Instant Tech News

Read More...

Global Marine Selective Catalytic Reduction System Market Industry: A Latest Research Report to Share Market Insights and Dynamics – News Parents

February 17th, 2020 9:55 pm

The Marine Selective Catalytic Reduction System Market is prepared through a rigorous and unique format to offer a high-quality, accurate, and valuable insight to assist in making strategic business choices. The preparation of the report required our experts to contemplate on global, regional, segmental, and other market figures such as revenue, volume, CAGR, and market share to provide reports of highest quality.

Crucial dynamics related to the financial outlooks of leading players such as PANASIA, Hitachi Zosen, MAN Energy Solutions, Agriemach, Hug Engineering, DCL International, etc. their research and development statuses, and their expansion strategies for the coming years have been also listed in the Global Marine Selective Catalytic Reduction System Market report. In addition, sales volume, price, revenue, gross margin, historical growth and future perspectives have also been included in the report.

Have some queries? Get Free Sample PDF Copy of Latest Research on Marine Selective Catalytic Reduction System Market @ https://www.acquiremarketresearch.com/sample-request/305365/

The report also provides a granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Following are some of the segmentations provided in the report ;

Leading players operating in the global Marine Selective Catalytic Reduction System market are: PANASIA, Hitachi Zosen, MAN Energy Solutions, Agriemach, Hug Engineering, DCL International, Caterpillar, ECOUREA, ME Production, DEC Marine

Marine Selective Catalytic Reduction System Market Growth by Types: Small Marine Engines, Medium Marine Engines, Large Marine Engines

Marine Selective Catalytic Reduction System Market Extension by Applications: Commercial, Offshore, Recreational, Navy, Others

The Global version of this report with a geographical classification would cover regions: North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Grab Your Report at an Impressive Discount! With Corporate Email ID @ https://www.acquiremarketresearch.com/discount-request/305365/

While segmentations have been provided to list down various facets of the Marine Selective Catalytic Reduction System market, analysis methods such as S.T.E.E.P.L.E., S.W.O.T., Regression analysis, etc. have been utilized to study the underlying factors of the market. Summarization of various aspects consisted in the report have been listed.

Here are the important points covered in the report: 1.Complete assessment of opportunities and risk factors involved in the growth of Marine Selective Catalytic Reduction System Market. Additionally, major events and innovations in Marine Selective Catalytic Reduction System Market report.2.Technological advancements and changing trends striking Marine Selective Catalytic Reduction System Market.3.Get to know about the leading market players, both current and emerging in the Global Marine Selective Catalytic Reduction System.4.The report focuses on global major leading Marine Selective Catalytic Reduction System Market players providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information.

Have Any Query? Ask Our Expert (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/enquire-before/305365/

About us:

At Acquire Market Research the database of the company is updated on a daily basis to provide the clients with reports containing the latest trends and in-depth analysis of the industry. While each report initially generated is prepared with a set benchmark of the industry, the reports are customizable to meet the requirements of the client. After careful validation of the report by our expert analysts, the report on Marine Selective Catalytic Reduction System Market has been published.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Read the original:
Global Marine Selective Catalytic Reduction System Market Industry: A Latest Research Report to Share Market Insights and Dynamics - News Parents

Read More...

Stem Cell Alopecia Treatment Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis and Forecast by 2026 – Instant Tech News

February 17th, 2020 9:55 pm

Stem Cell Alopecia Treatment Market Overview:

In the report, we thoroughly examine and analyze the Global market for Stem Cell Alopecia Treatment so that market participants can improve their business strategy and ensure long-term success. The reports authors used easy-to-understand language and complex statistical images, but provided detailed information and data on the global Stem Cell Alopecia Treatment market. This report provides players with useful information and suggests result-based ideas to give them a competitive advantage in the global Stem Cell Alopecia Treatment market. Show how other players compete in the global Stem Cell Alopecia Treatment market and explain the strategies you use to differentiate yourself from other participants.

The researchers provided quantitative and qualitative analyzes with evaluations of the absolute dollar opportunity in the report. The report also includes an analysis of Porters Five Forces and PESTLE for more detailed comparisons and other important studies. Each section of the report offers players something to improve their gross margins, sales and marketing strategies, and profit margins. As a tool for insightful market analysis, this report enables players to identify the changes they need to do business and improve their operations. You can also identify key electrical bags and compete with other players in the global Stem Cell Alopecia Treatment market.

Request a Report Brochure @ https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=ITN&utm_medium=001

Top 10 Companies in the Stem Cell Alopecia Treatment Market Research Report:

APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem, Sanford Burnham Prebys Medical Discovery Institute

Stem Cell Alopecia Treatment Market Competition:

Each company evaluated in the report is examined for various factors such as the product and application portfolio, market share, growth potential, future plans and recent developments. Readers gain a comprehensive understanding and knowledge of the competitive environment. Most importantly, this report describes the strategies that key players in the global Stem Cell Alopecia Treatment market use to maintain their advantage. It shows how market competition will change in the coming years and how players are preparing to anticipate the competition.

Stem Cell Alopecia Treatment Market Segmentation:

The analysts who wrote the report ranked the global Stem Cell Alopecia Treatment market by product, application, and region. All sectors were examined in detail, focusing on CAGR, market size, growth potential, market share and other important factors. The segment studies included in the report will help players focus on the lucrative areas of the global Stem Cell Alopecia Treatment market. Regional analysis will help players strengthen their base in the major regional markets. This shows the opportunities for unexplored growth in local markets and how capital can be used in the forecast period.

Regions Covered by the global market for Smart Camera:

Middle East and Africa (GCC countries and Egypt)North America (USA, Mexico and Canada)South America (Brazil, etc.)Europe (Turkey, Germany, Russia, Great Britain, Italy, France etc.)Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=ITN&utm_medium=001

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market, By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market, By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market, By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=ITN&utm_medium=001

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Alopecia Treatment Market Size, Stem Cell Alopecia Treatment Market Growth, Stem Cell Alopecia Treatment Market Forecast, Stem Cell Alopecia Treatment Market Analysis, Stem Cell Alopecia Treatment Market Trends, Stem Cell Alopecia Treatment Market

See original here:
Stem Cell Alopecia Treatment Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis and Forecast by 2026 - Instant Tech News

Read More...

Human Primary Cells Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2025 – News Parents

February 17th, 2020 9:55 pm

Human Primary Cells Market research report 2019 gives detailed information of major players like manufacturers, suppliers, distributors, traders, customers, investors and etc. Human Primary Cells market Report presents a professional and deep analysis on the present state of Human Primary Cells Market that Includes major types, major applications, Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export and etc. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report.The growth trajectory of the Global Human Primary Cells Market over the assessment period is shaped by several prevalent and emerging regional and global trends, a granular assessment of which is offered in the report. The study on analyzing the global Human Primary Cells Market dynamics takes a critical look at the business regulatory framework, technological advances in associated industries, and the strategic avenues.

Get Exclusively Free Sample Of This Report in PDF @ https://www.upmarketresearch.com/home/requested_sample/96652

Prominent Manufacturers in Human Primary Cells Market includes LonzaThermo Fisher ScientificSigma-AldrichCell BiologicsPromoCell GmbHCurelineZen-BioSTEMCELL TechnologiesCell ApplicationsPelobiotechCreative BioarrayCharles River LaboratoriesAxol BioscienceReachBio Research Labs

Market Segment by Product Types Epithelial CellsFibroblastsHematopoieticLiver CellsMesenchymal Stem CellsMuscle CellsPericytes

Market Segment by Applications/End Users MedicalSantific ResearchOther

In order to identify growth opportunities in the market, the report has been segmented into regions that are growing faster than the overall market. These regions have been potholed against the areas that have been showing a slower growth rate than the market over the global. Each geographic segment of the Human Primary Cells market has been independently surveyed along with pricing, distribution and demand data for geographic market notably: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

To Buy This Full or Customized Report, Please Visit https://www.upmarketresearch.com/buy/human-primary-cells-market-research-report-2019

Additionally, the complete value chain and downstream and upstream essentials are scrutinized in this report. Essential trends like globalization, growth progress boost fragmentation regulation & ecological concerns. Factors in relation to products like the products prototype, manufacturing method, and R&D development stage are well-explained in the global Human Primary Cells market research report with point-to-point structure and with flowcharts. It offers a comparative study between conventional and emerging technologies and the importance of technical developments in this market. At last, the market landscape and its growth prospects over the coming years have been added in the research.

For Any Information About This Report, Visit https://www.upmarketresearch.com/home/enquiry_before_buying/96652

The Questions Answered by Human Primary Cells Market Report: What are the Key Manufacturers, raw material suppliers, equipment suppliers, end users, traders and distributors in Human Primary Cells Market? What are Growth factors influencing Human Primary Cells Market Growth? What are production processes, major issues, and solutions to mitigate the development risk? What is the Contribution from Regional Manufacturers? What are the Human Primary Cells Market opportunities and threats faced by the vendors in the global Human Primary Cells Industry? What are the Key Market segments, market potential, influential trends, and the challenges that the market is facing?And Many More

Ask For Discount On This Report At https://www.upmarketresearch.com/home/request_for_discount/96652

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Website https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

Go here to see the original:
Human Primary Cells Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2025 - News Parents

Read More...

Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? – Forbes

February 17th, 2020 9:53 pm

A hamburger made out of cell-based meat by Mosa Meat, one of many companies throughout the world ... [+] creating beef and other animal products without the animal.

Up until now, plant-based food companies like Beyond Meat, Impossible Foods, and Quorn have almost singlehandedly worked to lessen the impacts of industrial animal agriculture.

Supermarket shelves and fast food restaurants across the US are serving up vegan burgers and meatballs and plant-based chicken nuggets are showing consumers there is an alternative to relying on animal-based protein.

But a quiet revolution is also taking place in labs, where scientists are working to cultivate meat and seafood grown from cells, with the potential to reduce demand for industrial animal agriculture even further.

Heres how the process works: Stem cells are taken from the muscle of an animal, usually with a small biopsy under anesthesia, then theyre put with nutrients, salts, pH buffers, and growth factor and left to multiply. Finessing the technology and getting the cost to an affordable level is happening at a slower pace than the plant-based industry, but a number of start-ups are nevertheless aiming to get their products on the market soon.

Memphis Meats' pan-seared cell-based chicken with sugar snap peas.

Cell-based meat (also known as cultured, cultivated, slaughter-free, cell-cultured, and clean meat) could be a common sight in supermarkets across the west in the next three years, according to theInstitute of the Future in Palo Alto. California-based Memphis Meats made headlines for its world-first cell-based meatballs four years ago, and iscurrently building a pilot plantto produce its cultured beef, chicken, and duck on a bigger scale with plans to launch more plants around the world.

And it isnt the only cell-based meat start-up in the The Golden State. Theres the recently formed San Francisco-basedArtemys Foods, co-founded by biochemist Jess Krieger, who has spent the past six years working at Kent State University in Ohio growing cell-based meat in a lab, Berkeley-basedMission Barns, focusedon creating animal fat, which it has mixed with other ingredients to make duck sausages, and San Diego-based BlueNalu, a startup developing seafood from fish cells through a process called cellular aquaculture.

Close up of BlueNalu's whole-muscle, cell-based yellowtail, beer-battered and deep-fried for fish ... [+] tacos.

But innovation isnt limited to the US its happening across the world.The global cell-based meat market is predicted to be worth$15.5m by 2021 and $20m by 2027,according to analysis.One report estimates that35% of all meat will be cultured by 2040.

While estimates vary, one study found that cell-based beef is projected to use 95 per cent fewer global greenhouse gas emissions, 98 per cent less land use and up to half as much energy. It also significantly reduces the amount of antibiotics needed, which are widely used in agriculture and contribute hugely to worseningantibiotic resistance. And since the animal cells are extracted humanely and grown in a facility rather than within the animals themselves, cell-based meat has the potential to all but eliminate animal suffering.

The industry has made huge progress since the first cell-based hamburger was unveiled in 2013 in London byDutch stem cell researcher Mark Post, chief scientific officer atDutch companyMosa Meat.While this was a huge achievement, it also showed the world how far the industry had to go before commercially viable cell-based meat could be a reality. It cost $325,000 to make, and wasnt totally animal-free, as most of the burgers muscle strands were grown with fetal bovine serum, which comes from blood drawn from bovine fetuses.

In the intervening years, Mosa Meat has made several breakthroughs, and aims to bring the price down to a commercial price. It now doesnt require fetal bovine serum, and hasdeveloped a process thatallows industrial scale production.

Cell-based tartar (raw minced beef, commonly eaten in some of the Northern European countries), ... [+] created by Mosa Meat.

Also in the Netherlands, start-up Meatable has recently raised 9m to help reduce costs and scale-up production of its beef and pork. It aims to havean industry-scale plant by 2025,and will have a small-scale bioreactor the machine where cell-growth takes place - this year.Meatables cofounder Krijn de Nood hopes tounveil its first prototype this summer.

Elsewhere in Europe, the UKs Higher Steaks is growing stem cells for the production of mince for pork sausages. Instead of using fetal bovine serum,the company uses protocols exclusively licensed to itby its collaborators, the University of Minnesota, that allow it to reprogram stem cells into muscle and fat tissues.

Instead of adult stem cells, it uses induced pluripotent stem cells, which means they have an infinite supply as the cells proliferate infinitely. With adult stem cells, researchers have to go to the animal every time they need a new batch.

AndSpains Cubiq Foodsis producing cell-based fat, which is used to enhance the flavor of food and enrich it with essential fatty acids, such as omega-3.

But when it comes to cell-based meat, all eyes are on Israel, where a number of start-ups likeFuture Meat Technologies and SuperMeat are making huge progress. The countrys interest in cell-based meat has also been attributed to its thriving vegan culture.

Comparison of Future Meat Technologies' cell-based chicken (left) to of farm-raised chicken (right). ... [+]

Future Meat Technologies, founded in 2018, has shortened the manufacturing process to two weeks, with a patent-pending method they say allows for higher production yields of cell-based beef. The start-up's technologies enable producers, farmers and retailers to manufacture biomass and process it locally. The company hopes toget cost down to $10 per poundby 2022.

As for SuperMeat, it is developing cell-based meat from chicken cells (it claimed during its launch in 2016 that it wasthe first company to work on clean chicken productsfor mass production). One of Europe's largest poultry producers,PHW-Gruppe formed a partnershipwith SuperMeat in 2018. We believe 2020 will be the tipping point for the cultivated meat industry, once the proof of scale will be introduced to the world, says Shir Friedman, Co-Founder and Chief Communications Officer of the company. SuperMeat is excited to take a lead part in this historical event."

An illustration of SuperMeat's cell-based meat cultivators of the future.

Another Israeli start-up,Aleph Farms, created the worlds first cell-based steak at the end of 2018.It was co-founded only one year prior together with The Kitchen Hub from the Strauss Group, and with Professor Shulamit Levenberg of the Technion Institute of Technology. And in fall of 2019,Aleph Farmssuccessfully3D printedmeat on the International Space Station. Our experiment ofbioprintingmeat in space... consisted of printing a small-scale muscle tissue using 3D Bioprinting Solutions bioprinting technology, says Yoav Reisler, External Relations Manager for the company. The proof of concept sought to assess the potential of producing cultivated meat in a zero-gravity environment away from land and local water resources. Our approach for cultivating beef steaks is imperative to the experiment, as it relies on mirroring the natural process of tissue regeneration that happens in a cows body but under controlled and animal-free conditions. Our overarching goal is to produce meat products that have a significantly reduced ecological impact and this was a milestone in towards achieving that. Earlier this month, Aleph Farms announced plans to open an educational complex next to its production facility to provide the general public a more in-depth view of how cell-based meat is grown.

Thin-cut beef steaks cultivated by Aleph Farms.

Also in Israel,BioFood Systemsaims to produce beef products using bovine embryonic stem cells. It also hopes to scale up technology that it can license globally toenable meatmanufacturers to produce their own cell-based meat.

But other parts of the world arent far behind Israel, including Asia. Singaporean Shiok Meats is working on bringing cell-based based crustaceans (shrimp, crab and lobster) to market, and says its the first company of its kind in Singapore and South-East Asia. It hopes to have a commercially viable product in the next few years, and is currently researching and developing.

Shiok Meats cell-grown shrimp dumplings.

And in Japan, meat producer Toriyama and its export agent, Awano Food Group has partnered with JUST to grow, distribute and sell its cell-based wagyu beef worldwide.

JUST doesn't yet have images of its cell-based wagyu because its still in early stage R&D, but it ... [+] may one day look like this animal-based piece of Wagyu beef steak seen here.

In-between Asia and Europe, innovation is also happing in Turkey. Biftek is the first and still the only companydeveloping cultured meat in the country. It uses a plant-based formulation, made up of 44 proteins, in place of fetal bovine serum. Founder Can Akcali said in a recent interview that the media in Turkey is showing a growing interest in its work, and cell-based meat more widely.

Since the first cell-based unveiling of a cell-based burger in 2013, scientists have been flocking to labs in a race to iron out numerous teething problems and be the first to make a commercially viable cell-based meat product. Meanwhile, private investment into the industry has soared. Last year, twelve companiesraised $50 million in 14 deals double the amount of 2018. US-based Memphis Meats raised $22 million, Spain's Cubiq Foods raised $14 million and Mosa Meat drew in $9 million.

Memphis Meats now plans to build a pilot production facility,thanks to additional investments in January this yearfrom Cargill and Tyson Foods, as well as high-profile investors Bill Gates, Richard Branson, and Kimbal Musk.

Ido Savir, SuperMeats chief executive, said Mosa Meat introduced the concept of cell-based meat to the world, and that the main challenge start-ups are still facing is proof of scaling up production to a commercially viable size that's cost-efficient. Once these hurdles are overcome, it will be a much smoother process to get cell-based meat on shelves. At the moment, cell-based products are being prototyped in labs - but once scientists have finessed the process and the cost, theyre produced at scale and can grow in facilities like any other food.

Many cell-based start-ups expect to get their products to market in the next few years. Whether or not they are actually able to meet that projection is an open question. I worry most startups in the cultured meat space are overestimating their short-term timeline to get to market and underestimating their potential long-term impact on completely redesigning our food system from the cell-level up, says Max Elder, Research Director in the Food Futures Lab at Institute for the Future. Regardless of the timeline, one thing is clear: we desperately need to undo the damage industrialized animal agriculture is wreaking on our communities, animals, and the planet. While it may indeed be unwise to count our cultured chickens before they hatch, especially in light of the urgent challenges we are facing, we can no doubt expect more innovation in the coming years. Perhaps one day - even if not in the near future - all the meat on our plates will indeed be slaughter-free.

Visit link:
Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? - Forbes

Read More...

The Benefits of Intermittent Fasting – The New York Times

February 17th, 2020 9:53 pm

Although there have been a number of recent studies assessing the effects of intermittent fasting on people, none are long term, and the vast majority of disease-related findings stem from research on laboratory animals. For example, in an animal model of stroke, those fed only intermittently suffered less brain damage because they were better able to resist the stress of oxygen and energy deprivation.

Other animal studies have shown a robust disease-modifying benefit of intermittent fasting on a wide range of chronic disorders, including obesity, diabetes, cardiovascular disease, cancers and neurodegenerative brain diseases, the researchers reported. Their review of both animal and human studies found improvements in a variety of health indicators and a slowing or reversing of aging and disease processes.

For example, human studies of intermittent fasting found that it improved such disease indicators as insulin resistance, blood fat abnormalities, high blood pressure and inflammation, even independently of weight loss. In patients with multiple sclerosis, intermittent fasting reduced symptoms in just two months, a research team in Baltimore reported in 2018.

If you think evolutionarily, Dr. Mattson said, predators in the wild fight for prey in the fasting state and are better at recovering from inevitable injuries. The human counterpart people who evolved in feast-or-famine environments would not have survived unless somehow protected by fasting.

Our human ancestors did not consume three regularly spaced large meals, plus snacks, every day, nor did they live a sedentary life, the researchers wrote. The studies they analyzed showed that most if not all organ systems respond to intermittent fasting in ways that enable the organism to tolerate or overcome the challenge and then return to normal.

Dr. Mattson explained that during a fast, the body produces few new proteins, prompting cells to take protein from nonessential sources, break them down and use the amino acids to make new proteins that are essential for survival. Then, after eating, a lot of new proteins are produced in the brain and elsewhere.

A reasonable question might be How safe is intermittent fasting? When fats are used for energy, they produce substances called ketone bodies that regulate the expression and activity of many proteins and molecules that are known to influence health and aging, the researchers reported. Ketosis, a build-up of acidic ketones in the blood, is a state that the Atkins diet, the ketogenic diet and other carbohydrate-restricted diets aim to achieve. Taken to extremes, however, ketosis can damage the liver, kidneys and brain and is especially dangerous to people with various chronic disorders like diabetes and heart disease.

Follow this link:
The Benefits of Intermittent Fasting - The New York Times

Read More...

Validea’s Top Five Healthcare Stocks Based On Motley Fool – 2/16/2020 – Nasdaq

February 17th, 2020 9:53 pm

The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

CORCEPT THERAPEUTICS INCORPORATED (CORT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

INMODE LTD (INMD) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

CRISPR THERAPEUTICS AG (CRSP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 72% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Motley Fool has returned 625.78% vs. 240.03% for the S&P 500. For more details on this strategy, click here

About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More here:
Validea's Top Five Healthcare Stocks Based On Motley Fool - 2/16/2020 - Nasdaq

Read More...

10 Best Clinics for Stem Cell Therapy in Costa Rica [2020 …

February 17th, 2020 9:51 pm

Stem Cell Therapy involves the use of stem cells to treat different diseases. These are non-differentiated cells of a multicellular organism. All the cells in the body are specialized for a specific function but they are the only cells without an assigned function. They can differentiate into any type of cell as and when required by the body and can proliferate rapidly to produce multiple copies of a specific type. Sources of stem cells are embryos and adult body tissues. In the adults, stem cells are present in bone marrow, brain, liver, skin, skeletal muscles, blood and blood vessels. While embryonic stem cells are derived from a blastocyst. Nowadays, Umbilical cord is being stored under suitable conditions to get stem cells from it if needed. This is useful as chances of transplant rejection are less because stem cells are derived from your own umbilical cord.

Bone Marrow Transplant is the most commonly used method to treat various types of cancers such as lymphoma, multiple myeloma, and leukemia, etc. through stem cells. It is also used to treat brain diseases, cardiovascular diseases and cell deficiencies such as diabetes mellitus. Recently, anti-aging stem cell treatments have gain fame. It is used to restore your youth and beauty.

The procedure of stem cell therapy starts with removing stem cells from your body or from the donors body. The cells are collected from different body parts depending upon the need. After collection, the cells are processed according to the purpose for which they are extracted. The processed stem cells are injected into the specific area of your body using ultrasound or X-ray guidance. Anesthetics are used and the procedure is done under sterile conditions. It is necessary to make sure that the cells are reaching the desired area so that the improvement is better and quicker. There are three types of stem cell transplant:

Each type of stem cell transplant involves different methods, procedures, and techniques with different side effects and risks. The one suitable for you depends upon your age, health, and physical conditions.

The length of stay in the hospital varies in accordance with the condition for which stem cell therapy is being done. It is usually a 3 to 4 hours procedure (in-patient) in which stem cells are introduced into the body using syringes or catheter. Different factors are considered to decide the length of your stay in the hospital. These factors are:

Your stay in the hospital is longer for an allogeneic transplant as compared to an autologous transplant and you're free to leave Costa Rica the very next day, although it's advised to stay at least a few days in case you have further questions for the medical staff. But of course, these can be asked over the phone/email or directed towards your local medical team back home.

Complete recovery time varies from 2 to 12 weeks when the patient begins to feel pain relief. However, you can return to your routine work a couple of days after going through the transplant. Recovery depends upon your physical condition before and after the transplant. Over a period of 6 to 12 months, further improvements are seen in the patients. During the process, antibiotics and other drugs are prescribed. These drugs prevent transplant rejection and graft-host diseases. Allogenic stem cell transplant takes longer to recover than an autologous transplant.

It is advised to keep in contact with your doctor and to visit him/her on a regular basis. Apart from this, the following points should be considered:

There is asignificant success rate seen in patients having gone through the transplant, however, it is not always successful due to various reasons, one being the transplant rejection. This is common in the allogeneic type of stem cell transplant.

Exosomes are being used as an alternative to stem cell therapy. They are lipid bilayer surrounded vesicles secreted by live cells. They contain mRNA, proteins, chaperons, and various signaling molecules. They work as a natural carrier system for the transport of these substances. They function as a messenger within the body carrying information from one cell to the other. Stem cell therapy can be enhanced using exosomes. They help the bodys natural healing ability to increase the pace of recovery. Sometimes, stem cell therapy and exosomes are given together for better results.

Stem cell therapy is mostly being used for the treatment of cancer patients. Before the therapy, cancer cells are present within the body. After going through the therapy, stem cells replace cancer cells with healthy cells. This treats cancer, giving the patient a healthy life.

Go here to see the original:
10 Best Clinics for Stem Cell Therapy in Costa Rica [2020 ...

Read More...

Should California invest another $5.5 Billion into stem cell research? – Long Beach Business Journal – Long Beach News

February 17th, 2020 9:50 pm

Over the past 15 years, Californias stem cell program has funded over 1,000 research, training and community engagement projects focused on stem cell technology in the state.

But in October of last year, the agency in charge of administering the states stem cell program awarded its last round of new funds, allocating the last of a total of $3 billion in funding approved by California voters. Now, the author of Proposition 71, which established the program in 2004, is seeking another round of $5.5 billion in funding for stem cell research in a measure vying for a spot on the Nov. 5 ballot.

The scientists and patient advocates in California have proven through the California stem cell initiative funding that they can change the future of medicine and human suffering, the measures author, Robert Bob Klein II told the Business Journal. California funding has filled the gap of the federal governments failure to fund this revolution in medicine.

Kleins interest in stem cell research and regenerative medicine arose from his youngest sons ultimately fatal battle with diabetes. Diagnosed with Type I Diabetes at age 11, Kleins son Jordan required human insulin-producing beta cells, the artificial production of which to the best knowledge of the scientific community at this point requires stem cells.

In 2016, 26-year-old Jordan Klein died of complications related to the disease, two years after scientists first made significant progress on finding a treatment developed with the help of human embryonic stem cells.

Klein blames the federal governments resistance to embracing stem cell research for the lack of adequate treatment options that lead to his sons death. My youngest son died. If they hadnt held it up in D.C., he would be alive, he said. How many children, how many adults are going to die before they create enough stability to advance therapies that mitigate or cure these chronic diseases?

For years, Klein a wealthy real estate developer had tried to affect change on the federal level, before shifting his attention to his home state. I became focused on what California could do, because the federal government was encumbered by religious issues, he explained.

Despite having no experience in the field of scientific research, Klein was able to mount a successful campaign, with 59.1% of California voters approving the creation of a state-funded stem cell program and an agency to govern it. The California Institute of Regenerative Medicine held its first meeting in December 2004 and issued its first round of funding in 2006, after battling several challenges to the proposition in state and federal court.

Since then, CIRMs funding has enabled conferences, translational research projects and clinical trials exploring cures for various types of cancers, diabetes and neurological disorders. While a majority of funding went to the University of Californias main campuses as well as regenerative medicine companies and institutes in major hubs like San Diego and the Bay Area, California State University, Long Beach and Torrance-based Pathways to Stem Cell Science have also received funds from CIRM.

CIRM has created a new industry in California that has been tremendously beneficial for the California economy, Dr. Victoria Fox, president of Pathways, told the Business Journal. Her company, which offers stem cell extraction and education services, has received both direct and indirect funding from CIRM.

Last year, Pathways hosted the SPARK Annual Meeting, an event that highlights the scientific accomplishments of students in the SPARK high school summer training program funded through a CIRM grant. Foxs company also provides educational services through CIRMs Bridges program at CSULB, in which students from state and junior colleges compete for six-month lab positions at UC research labs.

[These programs] are important to us, not only because they generate income to operate, but because they generate a workforce, Fox explained.

She said other companies often approach her in search of stem cell scientists. If voters decided not to extend funding for CIRM and its program in November, Fox said shed be hard-pressed to find an equivalent network for talent acquisition. I dont know where Im going to refer companies to find talent. I really dont know.

Dr. Aaron Levine, an associate professor at the School of Public Policy at Georgia Tech, has focused primarily on the intersection between public policy and bioethics. In this context, Levine has followed and reviewed Californias stem cell program for years, and he agreed that its impact has been transformative.

CIRM stepped in to fill a gap when the National Institutes of Health was restricting its funding in this space, Levine said. The research that CIRM has supported, as well as the training programs, has had quite a big impact on the field.

But Levine also pointed to what he described as missed opportunities, as the program enters its bid for renewal. One example is the new proposals requirement to commit a certain percentage of funds to finding cures for specific diseases, such as Alzheimers and other neurological disorders.

From a science policy perspective, I dont really like that. I would like the funding agency to have the flexibility to fund the best science they see submitted, the most promising science, Levine said. Klein argued that setting aside a certain percentage of funds for research on neurological diseases will ensure that they wont be left behind in favor of less costly research projects.

Levine also noted that the program has yet to resolve one crucial question: Who will pay for patients treatment with costly stem cell therapies once theyre ready to hit the market? Per-patient costs for stem cell therapies can easily reach several hundred thousand dollars and as research advances, more patients are expected to qualify.

Suddenly, thats just such a substantial sum of money that it becomes a fundamental challenge to how we pay for healthcare, how we pay for medicine in the United States, Levine said. Subsidies for California residents, whose taxes helped pay for the research necessary to bring these cures and therapies to market, would be one option, Levine noted.

Despite these concerns, Levine said he supports the measure to extend the program. Even though this is not the perfect measure, I think theres a lot of value in CIRM and it makes sense to continue it, he said. In the end, it will be up to California voters to decide.

It largely will rise and fall on whether theres a motivated campaign for and against it and what people whove never really thought about stem cell research as a state ballot issue are going to think about this particular initiative when it comes in the fall, Levine said.

See the rest here:
Should California invest another $5.5 Billion into stem cell research? - Long Beach Business Journal - Long Beach News

Read More...

JDRF Reaches New Milestones in Work to Drive Cures for Type 1 Diabetes and Improve Lives – PRNewswire

February 17th, 2020 9:50 pm

NEW YORK, Feb. 14, 2020 /PRNewswire/ -- JDRF, the leading global organization funding type 1 diabetes (T1D) research, funded $121.5 million directly and helped generate more than $400 million in total T1D research funds from nonprofits, government, and industry to propel a year of remarkable breakthroughs in 2019, JDRF announced today. JDRF research funding increased by 10 percent over the previous year.

"I am more excited about our progress than ever before, given the tremendous breakthroughs made in 2019," said Aaron J. Kowalski, Ph.D., president and CEO of JDRF. "We could not be driving this work forward without the support of so many dedicated individuals, partners and organizations all helping us deliver on our mission to cure T1D and improve lives."

JDRF funding supported more than 180 active T1D research grants and is funding about 70 clinical trials for drugs, biologic and devices to prevent or cure T1D. The organization also supported new investment through the JDRF T1D Fund in 15 T1D companies, including 11 focused on cures.

"We are focused on beta cell therapies and immune therapies to deliver cures for T1D," Kowalski said. "At the same time, we continue accelerating work in glucose control and complication therapies to improve the lives of those living with type 1 diabetes today."

Highlights of breakthroughs outlined in the 2019 Annual Report are:

Progress Toward Cures:

Improving Lives:

Reducing Complications:

JDRF's Annual Report also cites progress in advocacy and community engagement, two areas aimed at both supporting research and the T1D community. "The combined strengths of research, advocacy and community engagement are helping us support more members of the T1D community and enabling more people to support our mission," Dr. Kowalski said. "JDRF works to build partnerships that advance research and build and sustain critical support for type 1 diabetes (T1D) research funded by the Federal Government."

Expanding Access to Coverage:

Learn more about JDRF's research and advocacy priorities at jdrf.org and read the health insurance guide JDRF has complied to help the T1D community navigate their healthcare and health insurance here.

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact and uniting on a national stage to pool resources, passion and energy. We collaborate with academic institutions, policymakers and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.

SOURCE JDRF

Home

More:
JDRF Reaches New Milestones in Work to Drive Cures for Type 1 Diabetes and Improve Lives - PRNewswire

Read More...

I’m taking glucosamine for my arthritis. So what’s behind the new advice to stop? – The Conversation AU

February 16th, 2020 7:49 pm

The Australian Rheumatology Association this week warned people not to take the supplement glucosamine for their osteoarthritis due to possible allergic side-effects.

Whats the evidence behind this latest advice? And do you really need to stop taking it?

For years, glucosamine has been marketed as a treatment for osteoarthritis, which can occur when the protective cartilage in the joints wears down over time.

This is despite conflicting evidence on whether the supplement works. Yet many patients may buy glucosamine, presuming that even if it doesnt help, at least its natural and so wont do any harm.

Read more: Arthritis isn't just a condition affecting older people, it likely starts much earlier

But an Australian study, which has been online since last year and was cited in one of this weeks media reports, has given us more information about glucosamines safety.

The study found hundreds of allergic reactions to glucosamine have been reported to Australias medicines watchdog, the Therapeutic Goods Administration (TGA).

So is it safe for you to take glucosamine? In short, if it works for you and you havent had any side-effects, and your doctor and pharmacist know you are taking it, it is likely to be safe based on the multiple trials conducted to date.

Glucosamine is a naturally occurring substance the body uses to help build joint tissue, such as cartilage and tendons. In a supplement, the glucosamine can be made from the shells of prawns and other crustaceans, or it can be made synthetically in a factory.

Whether it works to manage osteoarthritis seems open to debate. The most recent evidence suggests little to no clinical benefit.

Read more: Science or Snake Oil: is glucosamine good for joints?

But advice to GPs about how to treat osteoarthritis says the issue isnt just confined to glucosamine.

When the Royal Australian College of General Practitioners looked at about 62 other medicines and possible treatments for osteoarthritis of the knee and hip (which include registered drugs and complementary medicines), none were backed by high-quality evidence to say they worked. Most of the evidence was based on low- or very low-quality studies.

The Australia study found 336 cases of side-effects to glucosamine (and to another supplement used for osteoarthritis called chondroitin) were reported to the TGA over 11 years. Of these, 263 cases were allergies, which ranged from mild to severe.

We dont know if these reactions included those from people with a known allergy to seafood or sulfur, as these would increase their risk of a reaction to glucosamine (glucosamine can come in different formulations, including glucosamine sulfate).

But a large percentage of people take glucosamine daily in Australia, with no ill effects. The cases reported to the TGA amount to just 30 people a year, with 16% of allergic reactions considered severe.

Beyond allergic reactions, there are other safety concerns about glucosamine.

For instance, if you are taking glucosamine and a medicine that thins your blood (such as warfarin after a stroke), this can increase your risk of bleeding.

Read more: Weekly Dose: Warfarin, the blood-thinner that's still used as a rat killer

Glucosamine supplements have also been implicated in chronic liver disease and in worsening underlying asthma. Some patients may also experience digestive symptoms such as heartburn.

The risks of other side-effects seem unclear, including whether it raises blood glucose levels in people with or without diabetes.

While the Australian Rheumatology Association has warned people to stop taking glucosamine, other advice is not so clear-cut.

Arthritis Australia reports glucosamine is a relatively safe treatment option for people with osteoarthritis and has relatively few side-effects compared with traditional medicines.

And the guidelines for GPs on how to manage osteoarthritis of the knee and hip makes a conditional recommendation not to use it, based on uncertainty over the balance of harms with potential benefit.

What should you do if youre taking glucosamine? If it works for you and you want to keep using it, then do so only on the advice of your doctor. Thats especially the case if you have any underlying medical conditions including diabetes, allergies or asthma.

Next, let your pharmacist know so they can check for any possible interactions with your other medicines, which can increase your risk of side-effects. You are most at risk if you are also taking warfarin, or any other type of blood thinning medicine.

Finally, if you do have unwanted side-effects from glucosamine, stop using it immediately and report it to your doctor.

Read more: The best foods for arthritis symptoms new research

Read the original:
I'm taking glucosamine for my arthritis. So what's behind the new advice to stop? - The Conversation AU

Read More...

Arthritis and Bipolar Disorder – PsychCentral.com

February 16th, 2020 7:49 pm

Studies reveal that people with rheumatoid arthritis are at a greater risk of developing bipolar disorder than the general population.

Specifics vary across studies, as does conjecture about the cause, but an analysis of several research filings state that people with RA are nearly 3 times more likely to have bipolar disorder.

Many researchers surmise that inflammation is the cause. RA is an autoimmune disorder, and neurologists are beginning to believe that even BP may be an autoimmune disease.

At 56 Im at an age where everything suddenly hurts, especially my joints. As this pain has spread to my hands and my knuckles have disfigured its time to get checked out for arthritis. I mean, I already have osteoporosis, which may be a result of my bipolar disorder or long-term use of anticonvulsants. Why not RA, too (then theres always hypochondria, which I wrote about here)?

Some of the data is contradictory. One study states that the average person with BP and RA is a 41-year old woman. Another only finds a relationship between the diseases in people under 19 and over 75. But a meta-analysis of a number of studies implies that the co-morbidity holds across populations, and the most common clinical features that co-occur with RA are psychiatric.

Its easy to point to stress as the common factor between the conditions, or even an inflammatory diet. But there may be a smoking gun lurking behind the data and the results.

That smoking gun is smoking.

Its well established that smoking is a contributing factor to RA. And any trip to a psych ward or the patio around the entrance of a building where a support group is meeting will quickly show that many people with bipolar disorder smoke. 68.8% of people with bipolar disorder currently smoke, and 82.5% of people with BP have smoked at some point during their lives. Of those who currently smoke, the average number of cigarettes smoked per day is 30.

So when it comes to the co-morbidity between BP and RA, maybe its not the BP at all. Maybe the true culprit is heavy smoking.

Medical research is hard, and drawing distinctions between correlation and causation is even harder. Just because diseases seem to occur together in lots of people doesnt mean that one causes the other.

The best way we can mitigate co-morbidity is to live as healthy a life as we can.

If you want to prevent or manage RA, you cant decide to not have BP. But you can manage stress, eat an anti-inflammatory diet and, above all else, stop smoking.

BP is difficult enough. We dont have to make it more difficult to live with by making choices, like smoking, that invite other health problems into our lives.

Sources:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167853/

https://www.sciencedirect.com/science/article/abs/pii/S0165032715303864

https://mdquit.org/special-populations/bipolar-disorder

Photo by handarmdoc

Link:
Arthritis and Bipolar Disorder - PsychCentral.com

Read More...

Updated EULAR Recommendations for Rheumatoid Arthritis Management With DMARDs – Rheumatology Advisor

February 16th, 2020 7:49 pm

Based on emerging new evidence and expert consensus, an international task force put together by the European League Against Rheumatism (EULAR) released updated recommendations for the management of rheumatoid arthritis (RA) with synthetic and biologic disease-modifying antirheumatic drugs (DMARDs). This report was published in Annals of the Rheumatic Diseases.

Investigators performed a systematic review of studies focused on the efficacy and safety of DMARDs as monotherapy or combination therapy, including conventional synthetic, targeted synthetic, and biologic DMARDs. The task force agreed on 5 overarching principles and 12 recommendations by devising related questions, eliciting expert opinions, and reaching consensus by vote.

Overarching Principles for Managing RA

1. According to the researchers, treatment of patients with RA should be based on shared decision-making between the patient and the treating rheumatologist. In addition, patient and provider education should be included in best care practices, which may increase adherence to medications and appropriate assessment strategies, respectively.

2. Researchers indicated that decisions regarding the treatment of patients with RA particularly when considering biologic and targeted synthetic DMARDs should be based on disease activity, safety issues, and other patient factors, including comorbidities and progression of structural damage.

3. Recommendations included that primary care for patients with RA should be provided by rheumatologists; it is especially important for patients with RA to receive specialty care when initiating any type of DMARD therapy.

4. The newest principle in managing patients with RA recognizes the heterogeneity of RA, in which the increasing number of drugs with different modes of action should be made accessible to patients as they may require multiple successive drug options throughout life to reach their therapeutic goal.

5. According to the researchers, RA is associated with a high economic burden to both patients and society; the treating rheumatologist should recommend drugs that are less costly compared with drugs that are more costly if efficacy and safety profiles are therapeutically similar.

Recommendations for Goals of Therapy

Therapy with DMARDs should be immediately initiated upon RA diagnosis as the disease will not remit spontaneously.

Sustained remission or low disease activity should be the primary goal in treating patients with RA, and both the American College of Rheumatology and EULAR agreed on the Boolean- and index-based definitions of remission.

Recommendations included the rapid attainment of the treatment target. It was agreed by the task force that disease activity should be assessed every 1 to 3 months; if no improvement is observed after 3 months or the target has not been achieved after 6 months, the treatment strategy should be adjusted.

Recommendations for First-Line Treatment Strategies

In treating patients with RA, methotrexate was recommended as first-line treatment. Investigators indicated that methotrexate is an efficacious conventional synthetic DMARD used as monotherapy but is also the basis for combination therapies with other DMARDs or glucocorticoids; dose escalation should occur within 4 to 6 weeks to reach a weekly dose of about 0.3 mg per kg.

If patients experience early intolerance or have a contraindication to methotrexate, the task force recommended that leflunomide or sulfasalazine be considered as part of first-line treatment strategy.

The EULAR recommended a short-term course of glucocorticoids as a bridging therapy when initiating or changing conventional synthetic DMARD therapies; once the treatment exhibits efficacy, rapidly tapering glucocorticoid use (within 3 months) is important.

Recommendations for Secondary Treatment Strategies

If the treatment target is not achieved after the first-line conventional synthetic DMARD strategy, other conventional synthetic DMARDs should be considered in the absence of poor prognostic factors. These factors include high disease activity and the presence of clinical features, as well as failure to achieve low disease activity after at least 2 conventional synthetic DMARDs.

If poor prognostic factors are present, and the treatment target is not achieved with the first conventional synthetic DMARD strategy, then the task force recommended adding a biologic DMARD or a targeted synthetic DMARD. Patient contraindications, preferences, and cost of care should be considered in deciding on combination therapy.

Recommendations for Combination Therapies

All biologic and targeted synthetic DMARDs are more efficacious in combination therapy compared with monotherapy; EULAR recommends that biologic DMARDs and targeted synthetic DMARDs be combined with a conventional synthetic DMARD. Among patients with contraindications to conventional synthetic DMARDs, interleukin-6 pathway inhibitors and targeted synthetic DMARDs may be used as comedication.

Researchers indicated that if a biologic DMARD or targeted synthetic DMARD therapy fails, treatment with another biologic DMARD or targeted synthetic DMARD should be considered. Similarly, if treatment with tumor necrosis factor inhibitor (TNFi) fails, patients may be effectively treated with a different mode of action or a second TNFi therapy.

Recommendations for Persistent Remission

If persistent remission is achieved after tapering any glucocorticoid bridging therapies, EULAR suggests that clinicians consider tapering biologic DMARDS or targeted synthetic DMARDs, especially when these therapies are combined with a conventional synthetic DMARD. Discontinuation of biologic DMARDs is often associated with flares, and tapering of biologic DMARDs may be preferred just as a dose reduction or interval increase.

Investigators indicated that if persistent remission is achieved with conventional synthetic DMARD monotherapy or if remission can be sustained after cessation of any added therapies from a combination therapy regimen, tapering the conventional synthetic DMARD may be considered.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please refer to the original reference for a full list of authors disclosures.

Reference

Smolen JS, Landew RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update [published online January 22, 2020]. Ann Rheum Dis. doi:10.1136/annrhumdis-2019-216655

Go here to see the original:
Updated EULAR Recommendations for Rheumatoid Arthritis Management With DMARDs - Rheumatology Advisor

Read More...

Possible link between rheumatoid arthritis and depression – Medical News Bulletin

February 16th, 2020 7:49 pm

Rheumatoid Arthritis (RA) is the most common autoimmune arthritis caused by the improper functioning of the bodys defense system. Research has shown that depression is among the most common mental health disorders associated with RA. However, the prevalence of concurrence ranges between 14% to 48% due to different factors including measurement methods, frequency of depressive symptoms and diagnosis threshold. Recent advances in clinical rheumatology have developed our understanding of RA and depression at a molecular level. However, several other studies need to be conducted to find the proportion and strong association between RA and depression among the population and find therapeutic treatments.

A recent study, published in the British Medical Journal showed that women suffering from RA exhibited depressive symptoms, which was linked to disease activity and dysfunction. A cross-sectional study comprising 319 female RA patients along with 306 healthy controls was conducted in Austria, based on Becks depression Inventory-Fast Screen (BDI-FS) a self-report to evaluate depression rate in patients suffering from medical disease. Factors including medication, alcohol intake, disease activity, smoking, and occupation were also evaluated in the study.

The results showed that depression was significantly higher in female patients (one-third of patients) suffering from RA as compared to the healthy controls. Furthermore, depressive symptoms were strongly linked with the disease disability and activity despite alcohol intake, age, occupation, and smoking status.

The study provided strong support for the rate of depressive symptoms among RA female patients. It should be noted, however, that pain assessment was not included in the study, and the study group consisted of only females. Further research will be necessary to confirm the findings and extend them further to enable potential treatment strategies.

Written by Sakina Bano Mendha

References:

April Chang-Miller, M. D. (2019, October 18). Is depression a factor in rheumatoid arthritis? Retrieved from https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/expert-answers/rheumatoid-arthritis-depression/faq-20119780

Sautner, J., Puchner, R., Alkin, A., & Pieringer, H. (2020). Depression: a common comorbidity in women with rheumatoid arthritisresults from an Austrian cross-sectional study. BMJ Open, 10(1). doi: 10.1136/bmjopen-2019-033958

Image byMabel Amber fromPixabay

Read more here:
Possible link between rheumatoid arthritis and depression - Medical News Bulletin

Read More...

Knee injuries in adults can lead to arthritis – The Straits Times

February 16th, 2020 7:49 pm

Young adults who have had knee injuries are much more likely than uninjured peers to develop arthritis in the knee by middle age, especially if they have broken bones or torn connective tissue, a study suggests.

Researchers followed almost 150,000 adults from ages 25 to 34, including about 5,200 with a history of knee injuries, for almost two decades.

Compared to people who never had knee injuries, those who did were nearly six times as likely to develop knee osteoarthritis during the first 11 years of follow-up, with more than triple the risk over the next eight years.

"Injuries that occur inside the knee joint, for example in the meniscus or cruciate ligament, may alter the biomechanical loading patterns in the knee," said study leader Barbara Snoeker, of Sweden's Lund University.

"Such injuries may lead to an imbalance in force transmissions inside the knee joint, consequently overloading the joint cartilage and leading to increased risk of developing osteoarthritis, compared to injuries that mainly affect the outside of the knee joint, such as contusions."

Osteoarthritis often affects the large weight-bearing joints and can eventually lead to the need for total joint replacement, the researchers noted in the British Journal of Sports Medicine.

Known risk factors include being overweight, older, female or having a job that puts a lot of stress on the joints, the study team note.

While a history of knee injuries is also a known risk factor, research to date has not offered a clear picture of whether certain types of injuries might be more likely to lead to osteoarthritis.

Two-thirds of the people in the study with knee injuries were male. After 19 years of follow-up, 422 people with knee injuries, or 11.3 per cent, developed knee osteoarthritis. So did 2,854, or 4 per cent, of people without knee injuries.

Most often, injuries involved multiple structures of the knee; this accounted for 21 per cent of participant knee injuries.

The second most common type of injury was cuts and contusions, at 18 per cent, followed by cartilage or other tissue tears at 17 per cent.

CRUCIATE LIGAMENT INJURIES

Damage to the tissue connecting the thighbone to the shinbone.

MENISCAL TEARS

Damage to cartilage connecting the same two bones.

FRACTURES OF THE SHINBONE

Where it meets the knee, or of the kneecap.

Cruciate-ligament injuries, or damage to the tissue connecting the thighbone to the shinbone, were associated with a 19.6 per cent greater risk of knee osteoarthritis, the study also found.

Meniscal tears, or damage to cartilage connecting the same two bones, were associated with a 10.5 per cent greater risk of osteoarthritis.

Fractures of the shinbone where it meets the knee, or of the kneecap, were associated with a 6.6 per cent greater risk.

Injuries involving multiple structures in the knee may have been under-reported, leading researchers to underestimate the risk associated with these types of injuries, said Jonas Bloch Thorlund, a professor of musculoskeletal health at the University of Southern Denmark, who was not involved in the study.

Another limitation is that researchers did not look at patient's body mass index (BMI), so they could not tell whether differences in weight might explain patients' risk of osteoarthritis, said Dr Kyle Hammond of the Emory Sports Medicine Centre in Atlanta.

What happens after knee injuries can also influence the risk of osteoarthritis down the line, said Hammond, who also was not involved in the study.

"Counselling a patient on how to safely and consistently return to a positive fitness programme ensures that they will maintain flexibility and strength, as well as keeping their weight at their ideal body weight," he said.

Rehabilitation matters, regardless of what other treatments patients receive, said Adam Culvenor, a sports and exercise medicine researcher at La Trobe University in Bundoora, Australia.

"Once these injuries occur, optimally managing them with an intense and progressive period of rehabilitation under the guidance of a physical therapist (irrespective of the decision to have surgery or not) to strengthen the muscles around the knee to facilitate a return to function and physical activity is likely to reduce the risk of osteoarthritis and persistent symptoms longer-term," Culvenor said by e-mail.

REUTERS

Visit link:
Knee injuries in adults can lead to arthritis - The Straits Times

Read More...

Real-World Patient Experience of Switching Biologic Treatment in Infla | PPA – Dove Medical Press

February 16th, 2020 7:49 pm

Karin Luttropp,1 Johan Daln,1 Axel Svedbom,1 Mary Dozier,2 Christopher M Black,3 Amy Puenpatom3

1ICON Clinical Research, Plc., Stockholm, Sweden; 2ICON Clinical Research, Plc., Boston, MA, USA; 3Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA

Correspondence: Amy PuenpatomCenter of Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ Tel +1 267 305 0620Fax +1 215 850 4549Email puenpatom.amy@merck.com

Purpose: To obtain an up-to-date overview of the measurement of patient experience of switching biologic treatment in patients with inflammatory arthritis (IA) or ulcerative colitis (UC). Secondary objectives included summarizing the types of patient-reported outcomes (PROs) used (if any), and related findings; and summarizing medical and non-medical reasons for treatment switch and/or discontinuation.Methods: A systematic literature review (SLR) was performed, searching Medline and Embase for relevant publications.Results: In total, 70 relevant publications were identified. While the majority of these reported reasons for switching and/or discontinuing treatment, only four provided information explicitly regarding patient-reported experience of switching biologic treatment. All four utilized ranking tools to assess patient experience of switching biologic treatment. The most common reason for switching and/or discontinuing treatment was loss of efficacy, while the least common reason was patient preference.Conclusion: Although the number of available treatments in IA and UC have increased, there is a sparsity of information regarding patient-reported experience of switching biologic treatment. Further research regarding patient preference and/or experience would benefit this therapeutic area and help guide treatment choices.

Keywords: arthritis, colitis, ulcerative, biological products, patient reported outcome measures, treatment switch

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read this article:
Real-World Patient Experience of Switching Biologic Treatment in Infla | PPA - Dove Medical Press

Read More...

Paddy McGuinness health: Top Gear presenters shock diagnosis at the age of 44 – Express

February 16th, 2020 7:49 pm

Osteoarthritis and rheumatoid arthritis are the two most common types of arthritis.

Osteoarthritis is the most common type of arthritis in the UK, affecting nearly nine million people.

It most often develops in adults who are in their mid-40s or older. It's also more common in women and people with a family history of the condition.

But it can occur at any age as a result of an injury or be associated with other joint-related conditions, such as gout or rheumatoid arthritis. Osteoarthritis initially affects the smooth cartilage lining of the joint.

This makes movement more difficult than usual, leading to pain and stiffness. Once the cartilage lining starts to roughen and thin out, the tendons and ligaments have to work harder.

This can cause swelling and the formation of bony spurs called osteophytes.

Severe loss of cartilage can lead to bone rubbing on bone, altering the shape of the joint and forcing the bones out of their normal position.

View original post here:
Paddy McGuinness health: Top Gear presenters shock diagnosis at the age of 44 - Express

Read More...

Former WABC-TV Eyewitness News Medical Reporter Joins New York Health – Long Island Weekly News

February 16th, 2020 7:49 pm

Millions of residents in the tristate area recognize Dr. Jay B. Adlersberg from his longtime position as the medical correspondent for WABC-TVs Eyewitness News. For 30 years, hes reported nightly on advances in the art and science of medicine. As an award-winning journalist and renowned rheumatologist and internist, Adlersberg provided his audience with well-explained insight on how scientific research relates to patients.

Now, Adlersberg is bringing that same commitment to patient care to New York Health.NY Health is a new, but rapidly growing network of independent board certified physicians with facilities in Manhattan, Queens, the Bronx, Nassau County and Suffolk County. Its specialties range from nephrology to urology, complemented with physical therapy. Through its parent company, New York Cancer Blood, NY Health has robust infusion centers that not only allow for advanced cancer treatments, but also allow Adlersberg to treat rheumatology patients in one place in less time.

Adlersberg, who has 45 years of experience treating the most severe forms of arthritis and joint disease, often employs intravenously-administered biologic medications like Humira to help patients achieve remission for debilitating conditions like rheumatoid arthritis. These drugs cannot be taken orally, and require patients to go to infusion centers for treatment. Prior to joining NY Health, Adlersberg would have to send patients to facilities outside his office to receive these life-changing infusions.

Joining NY Health was a no-brainer for me, Adlersberg said. Previously, I was sending patients to a different place for these infusions and if someone had a reaction to the drug, I couldnt see it. I would have to depend on nurses to describe it to me because I couldnt get to the place of infusion. Now, I have an office that is 40 feet away from the infusion center. If someone does have a reaction, I can walk right over and look and talk to the patient. That is the way I want to practice medicine, now I have a hand in everything that happens.

Dr. Jay Adlersberg

Adlersbergs new position at NY Health allows for a better, more personalized patient experience. Patients can now receive their infusions in one place in less than 90 minutes.

Previously, it would take three hours, Adlerberg said. They would have to sign in, and sign in a second time. It was a lot more paperwork and a lot more time consuming. Now, they can do it on a lunch hour if they wanted to. They will save so much time.

Adlersberg, brings a robust resume to NY Health. Aside from his award-winning reporting for WABC-TVs Eyewitness News, Adlersberg serves on the board of the New York chapter of the Arthritis Foundation. Educated at the University of Pittsburgh, where he graduated junior year Phi Beta Kappa and magna cum laude, he went on to graduate from the University of Pennsylvania School of Medicine, the nations oldest medical school and one of its most prestigious.

He completed a coveted residency at the countrys most respected city hospital and training ground for clinical medicine, the Bellevue Hospital Center of NYU Langone Medical Center. Adlersberg did his fellowship in rheumatology and immunology as an NIH-Postdoctoral Fellow at the Irvington House Institute of NYU Medical Center under the guidance of the late Dr. Edward C. Franklin, a world-renowned immunologist and member of the National Academy of Sciences.

Adlersberg, whose main interests are rheumatoid arthritis, the arthritis of psoriasis, back pain and autoimmune disorders, has been a forefront of intravenously administering biologic medications to treat his patient for two decades.

These drugs dont just treat the disease, Adlersberg said. They can essentially make it go away. I have been using them to treat patients for 20 years. One woman went from gaining 30 pounds because she couldnt go to the gym since her knees and ankles were so swollen and painful to going back to wearing high heels after four months of treatment.

Dr. Rohit Reejsinghani, executive director of NY Health, said the addition of Adlersberg is part of NY Healths commitment to creating a patient-centric model of care, through better connecting patients with their doctors for more personalized attention.

Dr. Adlersberg is one of the most respected rheumatologists in the country, Reejsinghani said. He invented the infusion game and because of that I said we need to have him on board. Our infusions centers are built within our cancer offices so having Dr. Adlersberg allows us to treat a different patient population within these state-of-the-art infusion centers. Bringing him on board will bring NY Health to the next frontier.

The rest is here:
Former WABC-TV Eyewitness News Medical Reporter Joins New York Health - Long Island Weekly News

Read More...

Page 700«..1020..699700701702..710720..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick